References
- Dixon M., Webb E. C. Enzymes 2nd edn. Longmans, Green, London 1964; 328
- Duncan J. D., Hallstrom G., Paulsen-Sorman U., Lindeke B., Cho A. K. Effect of α-carbon substituents on the N-demethylation of N-methyl-2-phenethylamines by rat liver microsomes. Drug Metabolism and Disposition 1983; 11: 15–120
- Hawes E. M., Roy S. D., McKay G., Midha K. K. Methoxyphenamine O-demethylase and 5-hydroxylase: A GLC-ECD assay to study their activities and their inhibition by debrisoquine and sparteine. Pharmacology and Therapeutics 1987; 33: 73–77
- Inaba T., Otton S. V., Kalow W. Deficient metabolism of debrisoquine and sparteine. Clinical Pharmacology and Therapeutics 1980; 27: 547–549
- Jurima M., Inaba T., Kalow W. Sparteine oxidation by the human liver: absence of inhibition of mephenytoin. Clinical Pharmacology and Therapeutics 1984; 35: 426–428
- Kupfer A., Al-Dabbagh S. G., Ritchie J. C., Idle J. R., Smith R. L. Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains. European Journal of Clinical Pharmacology 1982; 31: 3193–3199
- Larrey D., Distlerath L. M., Dannan G. A., Wilkinson G. R., Guengerich F. P. Purification and characterization of the rat liver microsomal cytochrome P-450 involved in 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. Biochemistry 1984; 23: 2787–2795
- Lowry O. H., Roseborough N. J., Farr A. L., Randal R. J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 1951; 193: 265–275
- McKay G., Cooper J. K., Hawes E. M., Roy S. D., Midha K. K. Identification of new secondary metabolites methoxyphenamine in man. Xenobiotica 1983; 13: 257–264
- Midha K. K., Cooper J. K., McGilveray I. J., Coutts R. T., Dawe R. Metabolism of methoxyphenamine in man and in monkey. Drug Metabolism and Disposition 1976; 4: 568–576
- Niwaguchi T., Inoue T. Excretion of methoxyphenamine and its metabolites in rat urine. Journal of Chromatography 1978; 161: 223–229
- Otton S. V., Inaba T., Mahon W. A., Kalow W. In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine. Canadian Journal of Physiology and Pharmacology 1982; 60: 102–105
- Otton S. V., Inaba T., Kalow W. Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. Life Sciences 1983; 32: 795–800
- Roy S. D. Methoxyphenamine metabolism in human oxidative phenotypes and their rat models. Ph.D. thesis, University of Saskatchewan, SaskatoonCanada 1985
- Roy S. D., Hawes E. M., McKay G., Midha K. K. Gas chromatographic quantification of methoxyphenamine and three of its metabolites in plasma. Journal of Chromatography and Biomedical Applications 1984; 310: 307–317
- Roy S. D., Hawes E. M., McKay G., Hubbard J. W., Midha K. K. Methoxyphenamine metabolism in rat models of human debrisoquine phenotypes. Canadian Journal of Physiology and Pharmacology 1985 a; 63: 778–781
- Roy S. D., Hawes E. M., McKay G., Korchinski E. D., Midha K. K. Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquine. Clinical Pharmacology and Therapeutics 1985 b; 38: 128–133
- Yamada H., Baba T., Hirata Y., Oguri K., Yoshimura H. Studies on N-demethylation of methamphetamine by liver microsomes of guinea pig and rats: the role of flavin-containing monooxygenase and cytochrome P-450 systems. Xenobiotica 1984; 14: 861–866